About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company s technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.
The Alliance for Regenerative Medicine: Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan
ATMPs are uniquely positioned to attack cancer at its source, bringing life-changing benefits to patients
BRUSSELS, BELGIUM - February 3, 2021
The Alliance for Regenerative Medicine (ARM) the global voice of the regenerative medicine and advanced therapies sector applauds the EU Beating Cancer Plan s identification of Advanced Therapy Medicinal Products (ATMPs) as part of a comprehensive cancer solution. ATMPs include cell and gene therapies that have already revolutionized the treatment of some aggressive forms of blood cancers and hold great promise for addressing other types of cancer.
Renowned Pioneers in Ophthalmology Join SparingVision s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
Paris, January 29, 2021 - SparingVision (the Company ), a genomic medicine company developing vision saving treatments for ocular diseases, today announces the strengthening of its Scientific Advisory Board ( SAB ) with the appointment of internationally renowned ophthalmology pioneers Dr. Paul A. Sieving, Professor of University of California Davis School of Medicine and the former Director of the US National Eye Institute, and Prof. Botond Roska, co-director of the Institute of Molecular and Clinical Ophthalmology Basel and Professor at the Medical and Science Faculty of the University of Basel.
About Silence Therapeutics plc Silence Therapeutics is developing a new generation of medicines by harnessing the body s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of comp
Tel: +44 (0) 20 7597 5970 Daniel Adams / Patrick Robb / Gary Clarence AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand
®, RESORBA
®, and LiquiBandFix8
®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal
® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.